Results 191 to 200 of about 103,562 (296)

Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation

Advanced Science, Volume 13, Issue 26, 8 May 2026.
ABSTRACT Extracellular vesicles (EVs) are nanoscale mediators of intercellular communication with diverse molecular cargoes that reflect their cell of origin. Advances in isolation, detection, and single‐particle analytics have revealed increasing molecular and functional heterogeneity, while exposing limitations in how EV identity and activity are ...
David J. Lundy, Zoe L. Chau, Sheng‐You Chen, Nanami Fujisawa, John J. Hill, Barnett M. Hsu, Joanne K. Liu, Karol W. Mai, James J. Lai   +8 more
wiley   +1 more source

Activation and DNA methylation of PANoptosis in polycystic ovary syndrome. [PDF]

PLoS One
Han Y, Han Y, Feng Y, Shan Y, Liu C, Wang K, Li X, Zhang S, Zhu X.   +8 more
europepmc   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Efficacy of Fertility‐Sparing Treatment With Progestin Is Associated With Different Molecular Classification in Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Cancer Medicine, Volume 15, Issue 5, May 2026.
Molecular profiles and outcomes of CR rate in 74 cases. ABSTRACT Objective To investigate the impact of various molecular characteristics on the outcomes of fertility‐preserving therapy in patients with endometrial cancer (EC) and atypical endometrial hyperplasia (AEH).
Xue‐Qian Qian, Hao‐Hui Fu, Xiao‐Yun Wan, Dong‐Xiao Hu, Yuan‐Ming Shen   +4 more
wiley   +1 more source

Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential. [PDF]

Front Endocrinol (Lausanne)
Natarajan M, E SH, Nataraj R.
europepmc   +1 more source

Luteolin Protects Against Noise‐Induced Hearing Loss via Mitigating Oxidative Stress and Apoptosis, With Potential Regulation of the EGR1/SPRY4 Axis

CNS Neuroscience &Therapeutics, Volume 32, Issue 5, May 2026.
Luteolin attenuates noise‐induced auditory hair cell loss, as well as TBHP‐induced oxidative stress and apoptosis. EGR1 modulates the transcription of SPRY4; the expression levels of both factors are upregulated following TBHP exposure, and this inductive effect is abrogated by luteolin treatment.
Jia‐ning Guo, Hong‐kai Mei, Rui Liang, Peng‐wei Ma, Wei‐long Wang, Jia‐wei Chen, Zi Wang, Hao Yuan, Yu‐qiang Lun, Wei Gao, Lian‐jun Lu   +10 more
wiley   +1 more source

Beyond Metformin: A Review of Non-pharmacological Treatments for Polycystic Ovary Syndrome. [PDF]

Cureus
Lakshmi PI, Kj S, Shetty P.
europepmc   +1 more source

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1223-1234, May 2026.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Gut Dysbiosis in Polycystic Ovary Syndrome. [PDF]

J Midlife Health
Garg R, Munshi A.
europepmc   +1 more source